Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2015

01-12-2015 | Research Article

RETRACTED ARTICLE: High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC)

Authors: Chen Gong, Yixin Zhang, Yinji Chen, Haifeng Zhang, Xiaorong Liu, Huaqing Xue, Li Ji, Liang Wang, Linlin Yang, Guoxiong Zhou, Chunhua Wan

Published in: Tumor Biology | Issue 12/2015

Login to get access

Abstract

Recent studies have identified that ErbB3 binding protein 1 (EBP1) is broadly expressed in various cancer tissues and critically involved in plenty of biological processes in this regard. However, the functional role of EBP1 in pancreatic ductal adenocarcinoma (PDAC) has never been elucidated. In this study, we found that EBP1 could serve as a prognostic biomarker of PDAC. Western blot analysis revealed that EBP1 was remarkably upregulated in PDAC tissues and cell lines. Using immunohistochemical analysis, we showed that the expression of EBP1 was correlated with tumor size (P = 0.004), histological differentiation (P = 0.041), and tumor node metastasis (TNM) stage (P = 0.000). Notably, Kaplan–Meier curve showed that high expression of EBP1 predicted significantly worsened prognosis of PDAC patients (P = 0.001). In addition, knockdown of EBP1 expression suppressed PDAC cell proliferation and retarded cell cycle progression. Furthermore, depletion of EBP1 induced the apoptosis of Panc-1 cells. Of great interest, we found that EBP1 interacted with anti-apoptotic protein, Bcl-xL, and promoted its accumulation. In summary, our results suggest that EBP1 is a novel prognostic indicator and potential therapeutic target of PDAC, shedding new insights into the important role of EBP1 in cancer development.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Costello E, Greenhalf W, et al. New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol. 2012;9:435–44.CrossRefPubMed
4.
Yoo JY, Wang XW, et al. Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin. Br J Cancer. 2000;82:683–90.CrossRefPubMedPubMedCentral
5.
Radomski N, Jost E. Molecular cloning of a murine cDNA encoding a novel protein, p38-2G4, which varies with the cell cycle. Exp Cell Res. 1995;220:434–45.CrossRefPubMed
6.
Xia X, Lessor TJ, et al. Analysis of the expression pattern of Ebp1, an ErbB-3-binding protein. Biochem Biophys Res Commun. 2001;289:240–4.CrossRefPubMed
7.
8.
Lessor TJ, Hamburger AW. Regulation of the ErbB3 binding protein Ebp1 by protein kinase C. Mol Cell Endocrinol. 2001;175:185–91.CrossRefPubMed
9.
Zhang Y, Woodford N, et al. Repression of E2F1-mediated transcription by the ErbB3 binding protein Ebp1 involves histone deacetylases. Nucleic Acids Res. 2003;31:2168–77.CrossRefPubMedPubMedCentral
10.
Squatrito M, Mancino M, et al. Ebp1 is a dsRNA-binding protein associated with ribosomes that modulates eIF2α phosphorylation. Biochem Biophys Res Commun. 2006;344:859–68.CrossRefPubMed
11.
Kim CK, Nguyen TLX, et al. Negative regulation of p53 by the long isoform of ErbB3 binding protein Ebp1 in brain tumors. Cancer Res. 2010;70:9730–41.CrossRefPubMed
12.
Zhang Y, Linn D, et al. EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. Mol Cancer Ther. 2008;7:3176–86.CrossRefPubMedPubMedCentral
13.
Sun J, Luo Y, et al. Expression of ERBB3 binding protein 1 (EBP1) in salivary adenoid cystic carcinoma and its clinicopathological relevance. BMC Cancer. 2012;12:499.CrossRefPubMedPubMedCentral
14.
Lessor TJ, Yoo JY, et al. Ectopic expression of the ErbB-3 binding protein ebp1 inhibits growth and induces differentiation of human breast cancer cell lines. J Cell Physiol. 2000;183:321–9.CrossRefPubMed
15.
Zhou H, Mazan-Mamczarz K, et al. Post-transcriptional regulation of androgen receptor mRNA by an ErbB3 binding protein 1 in prostate cancer. Nucleic Acids Res. 2010;38:3619–31.CrossRefPubMedPubMedCentral
16.
Hu B, Xiong Y, et al. The downregulation of ErbB3 binding protein 1 (EBP1) is associated with poor prognosis and enhanced cell proliferation in hepatocellular carcinoma. Mol Cell Biochem. 2014;396:175–85.CrossRefPubMed
17.
18.
Reichert M, Saur D, et al. Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. Cancer Res. 2007;67:4149–56.CrossRefPubMed
19.
Morton JP, Timpson P, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A. 2010;107:246–51.CrossRefPubMed
20.
Wan C, Hou S, et al. MIF4G domain containing protein regulates cell cycle and hepatic carcinogenesis by antagonizing CDK2-dependent p27 stability. Oncogene. 2013;34:237–45.CrossRefPubMed
21.
22.
Liu Z, Oh SM, et al. Human BRE1 is an E3 ubiquitin ligase for Ebp1 tumor suppressor. Mol Biol Cell. 2008;20:757–68.CrossRefPubMed
23.
Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22.CrossRefPubMed
24.
Lamb J, Ramaswamy S, et al. A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell. 2003;114:323–34.CrossRefPubMed
25.
26.
Kim CK, Lee SB, et al. Long isoform of ErbB3 binding protein, p48, mediates protein kinase B/Akt-dependent HDM2 stabilization and nuclear localization. Exp Cell Res. 2012;318:136–43.CrossRefPubMed
27.
Ko HR, Kim CK, et al. Phosphorylation of the N-terminal domain of p48 Ebp1 by CDK2 is required for tumorigenic function of p48. Molecular Carcinogenesis. 2014 n/a-n/a.
28.
29.
Ko HR, Nguyen TL, et al. P42 Ebp1 functions as a tumor suppressor in non-small cell lung cancer. BMB Rep. 2014.
30.
Ahn JY, Liu X, et al. Nuclear Akt associates with PKC-phosphorylated Ebp1, preventing DNA fragmentation by inhibition of caspase-activated DNase. EMBO J. 2006;25:2083–95.CrossRefPubMedPubMedCentral
31.
Okada M, Jang SW, et al. Ebp1 association with nucleophosmin/B23 is essential for regulating cell proliferation and suppressing apoptosis. J Biol Chem. 2007;282:36744–54.CrossRefPubMed
32.
Sengupta TK, Bose SK, et al. Identification of Ebp1 as a component of cytoplasmic bcl-2 mRNP (messenger ribonucleoprotein particle) complexes. Biochem J. 2006;396:99.CrossRefPubMedPubMedCentral
Metadata
Title
RETRACTED ARTICLE: High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC)
Authors
Chen Gong
Yixin Zhang
Yinji Chen
Haifeng Zhang
Xiaorong Liu
Huaqing Xue
Li Ji
Liang Wang
Linlin Yang
Guoxiong Zhou
Chunhua Wan
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3625-6

Other articles of this Issue 12/2015

Tumor Biology 12/2015 Go to the issue

Research Article

The clinicopathological significances and biological functions of parafibromin expression in head and neck squamous cell carcinomas

Original Article

TLR2∆22 (-196-174) significantly increases the risk of breast cancer in females carrying proline allele at codon 72 of TP53 gene: a case–control study from four ethnic groups of North Eastern region of India

Research Article

Knockdown of PLCε inhibits inflammatory cytokine release via STAT3 phosphorylation in human bladder cancer cells

Research Article

High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma

Review

The emerging role of Nemo-like kinase (NLK) in the regulation of cancers

Research Article

High-mobility group nucleosome-binding protein 1 is a novel clinical biomarker in non-small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits